Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SUPER NK is an allogeneic natural killer (NK) cell therapy product developed by Ascle Therapeutics. Positioned as a health and wellness product rather than a traditional clinical drug candidate, it is intended for applications in anti-aging, cancer prevention, and the management of hematological tumors. The product leverages the innate immune-surveillance capabilities of NK cells to identify and eliminate abnormal or senescent cells. While it shares the allogeneic NK cell platform used in Ascle's therapeutic pipeline (such as the ASC3xx series), SUPER NK is specifically marketed for longevity and preventative health, with sparse details regarding specific molecular targets or genetic modifications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SUPER NK.